Digital polymerase chain reaction (dPCR) technology has provided a new technique for
molecular diagnostics, with superior advantages, such as higher sensitivity, precision, and …

Outcomes of anticancer therapy vary dramatically among patients due to diverse genetic
and molecular backgrounds, highlighting extensive intertumoral heterogeneity. The …

In the era of new and mostly effective molecular targeted therapies, human epidermal
growth factor receptor 2 positive (HER2+) cancers are still intractable diseases. Lapatinib, a …

Most anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancers (NSCLCs)
show good clinical response to ALK inhibitors. However, some ALK‐rearranged NSCLC …

Abstract Aims Immune checkpoint inhibitors (ICIs) induce durable responses, but their
clinical benefits apply to only a subset of patients. Therefore, precisely predicting a patient's …

Background EGFR tyrosine kinase inhibitors (TKIs) have shifted the treatment paradigm in
advanced EGFR‐mutant non–small cell lung cancer (NSCLC). However, patients who are …

Several recurrent mutations and epigenetic changes have been identified in advanced
gastric cancer, but the genetic alterations associated with early gastric carcinogenesis and …

Small molecule tyrosine kinase inhibitors targeting HER 2 receptors have emerged as an
important therapeutic approach in inhibition of downstream proliferation and survival signals …

HER2-positive breast cancer (BC) is an aggressive subtype that affects 20–25% of BC
patients. For these patients, neoadjuvant therapy is a good option that targets a pathological …

Currently the clinical management of breast cancer relies on relatively few
prognostic/predictive clinical markers (estrogen receptor, progesterone receptor, HER2) …